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Abstract 
Purpose: Local breast cancer relapse after breast-saving surgery and radiotherapy is 
associated with increased risk of distant metastasis formation. The mechanisms 
involved remain largely elusive. We used the well-characterized 4T1 syngeneic, 
orthotopic breast cancer model to identify novel mechanisms of post-radiation 
metastasis. 
Experimental Design: 4T1 cells were injected in 20 Gy pre-irradiated mammary 
tissue, to mimic post-radiation relapses, or in non-irradiated mammary tissue, as 
control, of immunocompetent BALB/c mice. Molecular, biochemical, cellular, 
histological analyses, adoptive cell transfer, genetic and pharmacological 
interventions were performed.  
Results: Tumors growing in pre-irradiated mammary tissue had reduced 
angiogenesis, were more hypoxic, invasive and metastatic to lung and lymph nodes 
compared to control tumors. Increased metastasis involved the mobilization of 
CD11b+c-Kit+Ly6GhighLy6Clow(Gr1+) myeloid cells through the HIF1-dependent 
expression of KitL by hypoxic tumor cells. KitL-mobilized myeloid cells homed to 
primary tumors and pre-metastatic lungs, to give rise to CD11b+c-Kit- cells. 
Pharmacological inhibition of HIF1, silencing of KitL expression in tumor cells and 
inhibition of c-Kit with an anti-c-Kit blocking antibody or with a tyrosine kinase 
inhibitor, prevented the mobilization of CD11b+c-Kit+ cells and attenuated metastasis. 
C-Kit inhibition was also effective in reducing mobilization of CD11b+c-Kit+ cells and 
inhibiting lung metastasis after irradiation of established tumors.  
Conclusions: Our work defines KitL/c-Kit as a previously unidentified axis critically 
involved in promoting metastasis of 4T1 tumors growing in pre-irradiated mammary 
tissue. Pharmacological inhibition of this axis represents a potential therapeutic 
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strategy to prevent metastasis in breast cancer patients with local relapses after 
radiotherapy.  
 
Translational relevance 
Patients with local breast cancer relapse after conservative breast cancer surgery 
and radiotherapy have an increased risk of metastasis formation. To date there is no 
effective therapy to prevent progression to metastasis in these patients. Using a well-
characterized model of murine breast cancer, we identified the KitL/c-Kit axis as 
being critically involved in promoting metastasis of tumors growing in pre-irradiated 
mammary tissue. The mechanisms involve KitL-dependent mobilization of 
metastasis-promoting CD11b+c-Kit+Ly6GhighLy6Clow(Gr1+) myeloid cells. These 
findings have two immediate translational implications. Firstly, circulating CD11b+c-
Kit+ cells might be used as biomarkers to identify patients at risk for post-radiation 
metastasis. Secondly, inhibition of c-Kit could be an attractive approach to improve 
efficacy of radiotherapy or to prevent metastasis in breast cancer patients with local 
relapses after radiotherapy. Translational studies aimed at validating these results in 
patients are warranted.  
 
 
 
Key Words. Breast cancer, radiotherapy, metastasis, c-Kit, tyrosine kinase inhibitor 
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Introduction 
Adjuvant radiotherapy provides survival advantages compared to surgery alone 
and it is nowadays standard treatment in the management of several cancers, 
including breast cancer (1). Despite progress in the delivery mode, loco-regional 
post-radiotherapy relapses still occur in a fraction of treated patients. Relapses 
occurring within a pre-irradiated area are associated with an increased risk of local 
invasion, metastasis formation and poor prognosis compared to relapses occurring 
outside of the irradiated area including in breast (2) and head and neck cancers (3). 
Experimental evidence supports these clinical observations. In murine xenograft 
models, tumors developing within pre-irradiated beds are more invasive and 
metastatic compared to tumors growing outside irradiated beds, a condition also 
referred to as tumor bed effect (4, 5). One common feature of the tumor bed effect is 
the appearance of hypoxia (6-8), which is likely due to the inhibition of angiogenesis 
by ionizing radiations (9, 10). Tumor hypoxia is associated with increased 
invasiveness, greater risk of metastasis formation and shorter disease-free survival in 
different human tumors, including soft tissue sarcoma (11), head and neck (12), 
cervical (13) and breast cancers (14). In spite of its clinical relevance, the cellular and 
molecular mechanisms underlying the tumor bed effect are still not fully elucidated. 
Using human melanoma cells grafted in pre-irradiated, immunosuppressed mice, 
Rofstad and colleagues demonstrated that interleukin-8 (IL-8) and the receptor of 
urokinase-type plasminogen activator (uPAR) are important mediators of the tumor 
bed effect in this model (8, 15 ). We have previously shown that the matricellular 
protein cysteine rich protein 61 (CYR61) and integrin αVβ5 cooperate to promote 
invasion and metastasis of squamous cell carcinoma and colorectal adenocarcinoma 
growing subcutaneously in pre-irradiated, immunosuppressed mice (7).  
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Kit ligand (KitL), also known as stem cell factor (SCF) or Steele factor, is a cell 
surface protein existing in two alternatively spliced isoforms (16). One isoform 
contains a cleavage site that allows protease-mediated shedding from the cell 
surface as homodimeric soluble KitL, while the other one cannot be released and 
remains associated to the cell surface (17). KitL binds to the tyrosine kinase receptor 
c-Kit (18). During development KitL and c-Kit play critical roles in guiding cell 
migration, in particular at sites of hematopoiesis, in the central nervous system, in the 
gut and in the skin (melanogenesis) (19). C-Kit is down-regulated in adult tissues, 
except in hematopoietic stem/progenitor cells in the bone marrow, in melanocytes 
and in mast cells. Accordingly, after development the KitL/c-Kit axis is essential for 
the maintenance of hematopoiesis and for mast cell survival and function in 
peripheral tissues (20). In cancer c-Kit acts as oncogene in several tumors, in 
particular gastrointestinal stromal tumors (GIST), mastocytosis and melanoma (20), 
through activating mutations in the extracellular or intracellular domain (18), or 
through an autocrine KitL/c-Kit loop (21). The KitL also activates tissue-resident mast 
cells to generate a tumor-promoting angiogenic microenvironment (22, 23). A role of 
the KitL/c-Kit axis in metastasis formation, however, has remained unexplored.  
In this work we investigated cellular and molecular mechanisms underlying the 
tumor bed effect in breast cancer by using a model mimicking local relapse after 
radiotherapy. Presented results identify the KitL/c-Kit axis as a previously 
unsuspected mediator of metastasis in breast cancer.  
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Materials and Methods 
 
Antibodies, reagents and cell lines. Biotinylated rat anti-CD31 (MEC 13.3), FITC-
conjugated anti-CD11b (M1/70), PE-conjugated anti-c-Kit (2B8), APC-conjugated 
anti-CXCR4 (2B11), PE-conjugated rat IgG2b isotype control (A95-1) and 
CD16/CD32 Fc-Block (2.4G2) were purchased from BD Biosciences (Basel, 
Switzerland). PE-conjugated anti-CCR5 (HM-CCR5), unconjugated and PercP-
conjugated anti-F4/80 (BM8), PercP-conjugated anti-Sca1 (D7), Pacific blue-
conjugated anti-CD31 (390), unconjugated and Pacific blue-conjugated anti-CD11b 
(M1/70), APC-conjugated anti-CD45 (30-F11), FITC-conjugated anti-CD11c (N418), 
FITC-conjugated Harmenian Hamster IgG2 isotype control (HTK888), Alexa Fluor 
647-conjugated anti-Ly-6G, PerCP-conjugated anti-Ly-6C, PE-conjugated hamster 
IgG (HTK888), PercP-conjugated rat IgG2a (RTK2758) and Pacific blue-conjugated 
rat IgG2a (RTK2758) isotype controls were purchased from Biolegend (San Diego, 
CA). Pacific blue-conjugated anti-CD45 (30-F11), APC-conjugated anti-Gr-1 (RB6-
8C5), APC-conjugated anti-CD123 (5B11), APC-conjugated rat IgG2a isotype control 
and APC-conjugated rat IgG2b isotype control were purchased from eBioscience 
(San Diego, CA). APC-conjugated anti-VEGF-R1 (141522) was purchased from R&D 
(Abingdon, UK). LIVE/DEAD fixable near-IR dead cell stain kit and 4',6-diamidino-2-
phenylindole (DAPI) were purchased from Invitrogen (Basel, Switzerland). The 
hydroxyprobe-1 kit for detection of tissue hypoxia was obtained from HPI Inc, 
Burlington, MA. 4T1 cell line was generously provided by Dr. Fred R. Miller (Michigan 
Cancer Foundation, Detroit, MI) (24). HEPA-1 C1C7 and HEPA-1 C4 cells were 
obtained from Dr. Isabelle Desbaillet-Hakimi (CHUV, Lausanne, Switzerland). For all 
experiments, cells were grown in DMEM high glucose supplemented with 10% fetal 
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calf serum and 1% Penicillin/Streptomycin (all purchased from Invitrogen, Basel, 
Switzerland). For hypoxic treatment, cells were placed into a hypoxic chamber at 
0.1% O2. HIF1-inhibitor NSC-134754 (Developmental Therapeutics Program, 
NCI/NIH) was used at 1μM.  
 
Mouse model, irradiation and drug treatment. Adult (5-7 weeks of age) BALB/c 
female mice (Charles River Laboratories, Maastricht, The Netherlands) were used as 
host animals for grafted tumors. BALB/c mice expressing GFP under the Į-actin 
promoter were generously provided by Dr. S. Swain (Trudeau Institute, Saranac 
Lake, NY). Primary tumors were initiated by the injection of 4T1 tumor cells (5x104 
cells/mouse) into the right 4th mammary gland in 50ȝl of 1:5 mixture of Matrigel (BD 
Biosciences) and PBS. Before injection, the 4th mammary gland was locally irradiated 
with a single 20 Gy dose by using an X-ray unit (PHILIPS, RT 250, Germany), 
operated at a 125 kV, 20 mA, with a 2 mm Al filter. Drugs were administered as 
following: Clodrolip: 2 mg/20 g mouse body weight as initial dose, followed by 1 mg 
for the subsequent doses injected i.p. every 4th day starting from day 6; NSC-134754: 
5 mg/kg dose, injected i.p. daily from day 5; ACK2 (Biolegend): 50 μg dose, injected 
i.p. four times every 3rd day from day 10. Nilotinib (AMN107-AA, kindly provided by 
Novartis, Basel): 20 mg/kg dose, administered daily by gavage, from day 7. All animal 
experiments have been subjected to control and authorization by the cantonal 
veterinary service (Vaud and Fribourg). Tumor volume and lung metastases were 
assessed as previously described (7). For the quantification of lymphatic and liver 
metastases, axillary lymph nodes and liver sections were stained with HE and 
assessed for the presence of metastatic foci. For the irradiation of established 
tumors, 4T1 tumors were initiated as above, and when they were palpable (day 8 
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after tumor initiation) they were locally irradiated with the same settings (20 Gy, single 
dose). ACK2 treatment was performed as above.  
 
Flow cytometry. For flow cytometry on blood circulating cells, 50 ȝl of fresh blood 
were collected from the tail vein in 3 ȝl of 0.5M EDTA. Bone marrow resident cells 
were collected from femoral bones and filtered to form single-cell suspensions. For 
flow cytometry analyses on tumors and lungs, mice were perfused with PBS by 
intracardiac injection. Mammary tissue, tumors and lungs were excised, mechanically 
disrupted, enzymatically digested and then filtered to obtain single-cell suspensions. 
Staining and acquisition were done as described (25). Samples were acquired with a 
FACS LSR II, FACScalibur (Becton-Dickinson, Basel, Switzerland) or MACS Quant 
Analyzer Miltenyi (Teterow, Germany) and data analyzed using FCS Express Version 
3 (De Novo Software, Los Angeles, CA) or FlowJo (Tree Star, Inc.Ashland, OR). 
 
c-Kit+ cell depletion and fluorescence-activated cell sorting. PBMCs were 
isolated using the Ficoll procedure. To asses the effect of circulating c-Kit+ cells on 
metastasis, 10x106 PBMCs were injected at day 8 and 12 either directly or after 
depletion of c-Kit+ cells using the EasySep® Magnet procedure according to the 
manufacturer’s instructions (Stemcell Technologies, Grenoble, France). For in vivo 
cell tracking, PBMCs were sorted using FACS Aria (Becton-Dickinson). The purity of 
the sorted samples was assessed by direct flow cytometry re-analysis and viability of 
the cells estimated with Trypan blue staining. 2x106 c-Kit+ cells were then injected 
intravenously in 4T1-bearing mice.  
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Statistical analyses. Statistical comparisons were performed by a two-tailed 
Student’s t test or one-way ANOVA with Bonferroni post-test using Prism 5.0 
GraphPad Software (La Jolla, CA). Results were considered to be significant with p < 
0.05. *, p < 0.05; **, p < 0.01; ***, p < 0.001.  
 
Additional methods are available as supplementary material on line. 
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Results 
 
Tumors growing in pre-irradiated mammary tissue have decreased vascular 
density, are more hypoxic, invasive and metastatic 
To investigate the effect of mammary tissue irradiation on breast cancer 
progression, we pre-irradiated the 4th mammary gland of BALB/c mice with 20 Gy X-
ray single dose before implanting 4T1 tumor cells (24). While in current clinical 
practice adjuvant radiotherapy in breast cancer is delivered in fractionated doses, in 
this model it was not possible to perform multiple irradiations because of technical 
and ethical issues. Nevertheless, the single X-ray dose was chosen to correspond to 
the cumulative dose of approximately 60 Gy delivered to breast cancer patients 
during fractionated therapy (26). Mammary tissue pre-irradiation had no significant 
effect on 4T1 primary tumor growth (Supplementary Fig. S1A). Tumors growing in a 
pre-irradiated mammary tissue showed reduced microvascular density, increased 
hypoxia and necrosis (Fig. 1A), consistent with radiation-induced inhibition of 
angiogenesis (9, 10). They were also more invasive into the surrounding muscle and 
fat tissues (Fig. 1B), and more metastatic to ipsilateral axillary lymph nodes (Fig. 1C), 
lungs (Fig. 1D) and liver (Supplementary Fig. S1B).  
These results demonstrate that 4T1 breast tumors growing in a pre-irradiated 
mammary tissue undergo a tumor bed effect that recapitulates clinically relevant 
features of breast cancers locally relapsing after radiotherapy.  
 
Tumors growing in pre-irradiated mammary tissue recruit metastasis-
promoting CD11b+ cells 
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In tumor growing in pre-irradiated beds we observed a significant increase in 
the recruitment of CD11b+ myeloid cells, and of two subpopulations thereof, 
CD11b+F4/80+ and CD11b+Gr1+ (Fig. 2A and Supplementary Fig. S2A). Irradiation of 
the mammary tissue without tumor implantation did not induce recruitment of CD11b+ 
myeloid cells (Fig. 2A). Enhanced recruitment occurred in the tumor periphery as 
demonstrated by F4/80 staining (Fig. 2B). Treatment with Clodrolip to deplete 
phagocytic myeloid cells (27) did not affect primary tumor growth (Supplementary 
Fig. S2B), but significantly reduced the number of CD11b+ and F4/80+ cells in the 
tumor (Fig. 2C, Supplementary Fig. S2C, left panel, and S2D), microvascular density 
(Supplementary Fig. S2C, right panel, and S2D), and lung metastasis formation (Fig. 
2D and Supplementary Fig. S2E).  
These results demonstrate that mammary tissue irradiation enhances 
recruitment of CD11b+ cells contributing to lung metastasis formation.  
 
HIF1-dependent Kit ligand expression in hypoxic tumor cells promotes 
metastasis 
Hypoxic tumors can mobilize bone marrow-derived cells by releasing soluble 
factors (28). We therefore screened for cytokines induced by hypoxia in 4T1 cells and 
potentially involved in CD11b+ cell mobilization. In addition to VEGF-A and MCP-1, 
Kit-ligand (KitL) was among the cytokines significantly induced by hypoxia (24 hours, 
0.1% O2) in 4T1 cells in vitro at both the mRNA and protein levels (Fig. 3A and 
Supplementary Fig. S3A). Since bone marrow-derived cells expressing the KitL 
receptor c-Kit (20) are present in the pre-metastatic niche (29), but the putative role 
of KitL/c-Kit axis in metastasis formation has not been assessed yet, we decided to 
focus on KitL. VEGF-A expression was monitored as a control for effective hypoxia 
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and activity of the HIF1 inhibitor NSC-134754 (30) (Supplementary Fig. S3A and 
S3B). Inhibition of HIF1 in 4T1 cells by NSC-134754 and genetic deficiency of the β 
subunit of the HIF complex in HEPA1 cells prevented hypoxia-induced up-regulation 
of KitL mRNA and protein (Fig. 3A, Supplementary Fig. S3B and S3C). 4T1 tumors 
growing within a pre-irradiated bed had increased KitL protein (Fig. 3B) and mRNA 
(Supplementary Fig. S4A) levels, and this increase was blunted by NSC-134754 
treatment (Fig. 3B). Mammary tissue irradiation alone did not induce KitL expression 
(Supplementary Fig. S4B). Plasma levels of KitL were higher in pre-irradiated tumor-
bearing mice compared to controls (Fig. 3C) demonstrating systemic release of KitL 
(31). In contrast, CXCL12, a chemokine previously reported to promote CD11b+ cell 
recruitment within irradiated tumors (32), was not induced in this model 
(Supplementary Fig. S4C). Silencing of KitL expression in 4T1 cells through 
lentiviral–mediated expression of KitL-specific short-hairpin (sh) RNAs 
(Supplementary Fig. S4D and S4E) suppressed lung metastasis formation of 4T1 
tumors growing in pre-irradiated mammary tissue (Fig. 3D), while it did not affect 4T1 
tumor cell growth in vitro or in vivo (Supplementary Fig. S4F and S4G). 
These results demonstrate that KitL expression is induced by hypoxia in a HIF1-
dependent manner, and that KitL is required for increased metastatic spreading, but 
not primary growth, of 4T1 tumors implanted in pre-irradiated mammary tissue. 
 
KitL mobilizes CD11b+c-Kit+ cells 
To ascertain cells responding to KitL we set up to identify c-Kit-expressing cells 
in tumor-bearing mice. C-Kit expression was undetectable on CD45- and CD45+ cells 
recovered from primary tumors, while it was detectable at low frequency on bone 
marrow cells and circulating CD45+ myeloid cells (Fig. 4A and Supplementary Fig. 
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S5A). C-Kit+ cells were virtually undetectable in the blood of tumor-free mice (Fig. 
4B). Circulating c-Kit+ cells in pre-irradiated, tumor-bearing mice expressed CD11b 
and Gr1 but were negative for F4/80, CCR5, CXCR4, VEGF-R1, Sca1 and CD123 (a 
marker for mast cells) (33) expression (Supplementary Fig. S5B). Their morphology 
was consistent with young, immature myeloid cells (Supplementary Fig. S5C). 
Circulating c-Kit+ cells were unable to form hematopoietic colonies, in contrast to 
bone marrow-derived c-Kit+ cells (Supplementary Fig. S5D). Further phenotypical 
analysis revealed that circulating c-Kit+CD11b+ cells were Ly6Ghigh and Ly6Clow and 
CD11c negative (Supplementary Fig. S6A and S6B). Tumor-infiltrating CD11b+ cells 
were predominantly Ly6Ghigh  (Supplementary Fig. S6C). The Ly6GhighLy6Clow 
phenotype is indicative of CD11b+ granulocytic myeloid-derived suppressor cells 
(MDSC) (34), consistent with the well documented ability of 4T1 tumors to expand 
and mobilize MDSC (35, 36). Tumors implanted in pre-irradiated mammary tissue, 
but not mammary tissue irradiation alone, significantly enhanced the frequency of 
circulating CD11b+c-Kit+ cells, compared to control tumors (Fig. 4B), and KitL 
silencing in 4T1 tumor cells or systemic administration of NSC-134754 significantly 
reduced it (Fig. 4C).  
 
Mobilized CD11b+c-Kit+ cells home to tumors and pre-metastatic lungs in a 
KitL-dependent manner 
To monitor the fate of circulating c-Kit+ cells we isolated circulating 
GFP+CD11b+c-Kit+ cells from tumor-bearing GFP-BALB/c mice (over 95% enriched, 
not shown) and injected them into recipient BALB/c mice bearing 4T1 tumors 
implanted in pre-irradiated mammary tissue. Six hours after intravenous injection, 
GFP+CD11b+ cells were detectable in the blood and in tumor tissue, however, only 
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approximately 25% and none of the transferred cells retained c-Kit expression, 
respectively (Fig. 5A). KitL silencing in 4T1 tumors significantly reduced radiation-
induced recruitment of CD11b+ cells to primary tumors (Fig. 5B). In a second 
adoptive transfer experiment we demonstrated that GFP+CD11b+c-Kit+ cells also 
home to lungs of BALB/c recipient mice bearing tumors growing in pre-irradiated 
mammary tissue, with only approximately 25% of them retaining c-Kit expression 
(Fig. 5C). C-Kit+ cells were also present in lungs of tumor-bearing mice 15 days after 
tumor implantation, and their frequency increased in mice bearing tumors growing in 
pre-irradiated beds compared to non-irradiated controls. This increase was blunted 
by KitL silencing in tumor cells (Figure 5D).  
These results indicate that tumor-derived KitL mobilizes CD11b+c-Kit+ cells to 
home to primary tumors and pre-metastatic lungs, but once recruited the rapidly lose 
c-Kit expression. 
 
Mobilized CD11b+c-Kit+ cells promote lung metastasis 
To obtain evidence whether tumor-mobilized c-Kit+ myeloid cells promote lung 
metastasis, we isolated peripheral blood mononuclear cells (PBMCs) from pre-
irradiated tumor-bearing mice, and injected either the total PBMCs or PBMCs 
depleted of c-Kit+ cells (Supplementary Fig. S7A) into non-irradiated tumor-bearing 
mice and monitored lung metastasis formation. Transfer of total PBMCs increased 
lung metastasis by about 5 fold, while transfer of c-Kit+ cell-depleted PBMCs resulted 
in a significantly reduced increase in lung metastasis (Fig. 6A). No effects on primary 
tumor growth were observed (Supplementary Fig. S7B).  
These results indicate that mobillized CD11b+c-Kit+ cells significantly contribute 
to promote lung metastasis. 
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c-Kit inhibition reduces mobilization of CD11b+c-Kit+ cells and attenuates lung 
metastases 
To test whether inhibition of c-Kit impinges on lung metastasis formation, we 
treated pre-irradiated, tumor-bearing mice with the anti-c-Kit blocking antibody ACK2 
(Ref. (37)). ACK2 treatment suppressed radiation-induced mobilization of c-Kit+ cells, 
accumulation of CD11b+ cells in primary tumors (Fig. 6B) and attenuated lung 
metastasis formation by approximately 50% (Fig. 6C, upper panel). Treatment with 
nilotinib (AMN107-AA), a tyrosine kinase inhibitor that effectively block c-Kit activity 
(38), suppressed lung metastasis formation to a similar extent (Fig. 6C, lower panel). 
ACK2 or nilotinib treatments did not impinge on primary tumor growth 
(Supplementary Fig. S7C and S7D). To assess whether this mechanism may also 
apply to irradiated tumors, we irradiated established 4T1 tumors. Irradiation 
significantly delayed tumor growth and increased lung metastasis (Supplementary 
Fig. S8A and S8B). Treatment with ACK2 reduced the frequency of circulating 
CD11b+c-Kit+ cells and the number of lung metastases (Supplementary Fig. S8C and 
S8D) without impinging on tumor growth (Supplementary Fig. S8E).  
These results demonstrate that c-Kit activity is critically involved in mediating 
the mobilization of CD11b+c-Kit+ cells and in promoting lung metastasis formation of 
4T1 tumors growing in pre-irradiated mammary tissue or after tumor irradiation.  
 
Discussion 
In spite of their clinical relevance, the cellular and molecular mechanisms 
mediating metastasis of tumors locally relapsing after radiotherapy are still largely 
elusive. In this work we using the well-characterized 4T1 murine breast cancer 
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model, we discovered a novel mechanism promoting metastasis of breast cancer 
growing in a pre-irradiated bed.  
The main novel finding is the identification of the KitL/c-Kit axis as a crucial 
element of this mechanism. We show that tumors growing in a pre-irradiated bed are 
poorly vascularized and hypoxic, and that hypoxia induces HIF1-dependent KitL 
expression by tumor cells. Released KitL mobilizes CD11b+c-Kit+Ly6GhighLy6Clow 
(Gr1+) myeloid cells, which recruit to primary tumors and to lungs and facilitate lung 
metastasis formation. Expression of KitL in peri-necrotic tumor regions was reported 
in human cancers, including breast cancer, and correlates with progression (39). The 
tumor-promoting effect of KitL was considered due to KitL stimulating c-Kit+ tumor 
cells or c-Kit+ endothelial cells and mast cells, resulting in enhanced cell growth (40), 
angiogenesis (41) and immunosuppression (42). 
The second main finding is the identification of CD11b+c-Kit+Ly6GhighLy6Clow 
(and F4/80-CCR5-CXCR4-Flt1-CD123-) cells as novel CD11b+ sub-population with 
metastasis-promoting activity. Recruited CD11b+c-Kit+ cells rapidly lose c-Kit from 
their surface, to give rise to CD11b+c-Kit- cells, which may be the actual cells 
promoting metastasis. This is consistent with the enriched presence of CD11b+ cells 
at the invasive tumor front and the observed reduced metastasis formation following 
depletion by Clodrolip. CD11b+ cells are known to promote tumor growth, invasion 
and metastasis through multiple mechanisms, including angiogenesis (43), 
vasculogenesis (10, 32), immunosuppression (44), lymphangiogenesis (45) and 
tumor cell motility (46). Taken together, our results identify KitL as a factor inducing 
the mobilization and recruitment to tumors and lungs of CD11b+  myeloid cells, in 
addition to already identified factors, such as including VEGF-A (47), CXCL12 (48), 
CXCL5 (46) and PlGF (49). We are currently investigating the mechanisms by which 
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CD11b+c-Kit+ cells (and CD11b+ c-Kit- cells derived thereof) promote metastasis. The 
reduced microvascular density induced by Clodrolip treatments in tumors growing in 
a pre-irradiated bed suggests that these cells possess vessel-forming properties, 
possibly by vasculogenesis, as recently reported (32). The Ly6GhighLy6Clow 
phenotype consistent with a granulocytic MDSC population (34) also raises the 
possibility that immunosuppressive effects might contribute to promote metastasis.  
These results have two immediate translational implications. Firstly, they 
identify circulating CD11b+c-Kit+ cells as candidate biomarkers to stratify patients at 
risk for post-radiation metastasis. We have attempted to validate this hypothesis 
using archive material, but the limited number of cases identified and restrictive local 
ethical regulations hindered this approach. Preliminary analyses in humans indicate 
that CD11b+c-Kit+ are present at low frequency in the peripheral blood of healthy 
volunteers, and at higher frequency in patients with metastatic breast cancer.  
Secondly, they point to the KitL/c-Kit axis as a potential therapeutic target to 
prevent metastasis of post-radiation breast cancer relapses. C-Kit inhibition by 
tyrosine kinase inhibitors (TKI) is already used to treat cancers with uncontrolled c-Kit 
activity (50) (due to c-Kilt overexpression, mutational activation or KitL 
overexpression), including GIST (51) and melanoma (52). Here, stable silencing of 
KitL in 4T1 tumor cells, selective c-Kit inhibition by the ACK2 mAb and treatment with 
nilotinib, a clinically approved TKI that effectively block c-Kit activation (38), all 
reduced metastasis of tumors growing in a pre-irradiated mammary tissue. C-Kit 
inhibition also reduced lung metastasis formation of 4T1 tumor that were treated with 
radiotherapy. Based on these findings, inhibition of c-Kit should be explored as a 
possible adjuvant approach in patients with local recurrences after radiotherapy and 
at increased risk for metastatic progression. It is important to note that these findings 
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are based on one breast cancer cell line only, 4T1. This line is known to induce an 
unusually strong mobilization of MDSC, which may not occur in all breast cancer 
models. It will also be important to ascertain whether in human breast cancer this 
mechanism is common to all breast cancer types, or whether it is specific for a 
particular breast cancer subtype. To this purpose we are interrogating additional 
experimental breast cancer models and initiating a clinical study to monitor the 
frequency of circulating CD11b+c-Kit+ cells in breast cancer patients, before, during 
and after surgery/radiotherapy. Monitoring CD11b+c-Kit+ cells in the circulation might 
also be a simple strategy to identify patients with an active KitL/c-Kit axis that may 
benefit from c-Kit inhibition.  
Taken together we have demonstrated that hypoxic breast tumors growing in a 
pre-irradiated environment mobilize CD11b+c-Kit+Ly6GhighLy6Clow granulocytic MDSC 
through HIF1-mediated KitL release. These observations extend our understanding 
of the mechanisms of metastasis of tumors growing in a pre-irradiated bed by 
implicating for the first time the KitL/c-Kit axis in this effect (Fig. 6D). Translational 
studies aimed at validating these results in patients are warranted. 
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Figure legends 
 
Figure 1. Breast cancer cells growing in a pre-irradiated mammary tissue are 
highly invasive and metastatic. A, 4T1-derived tumors growing in a pre-irradiated 
mammary tissue had reduced microvascular density (MVD; CD31 staining, red; bar: 
100 μm), were more hypoxic (pimonidazole staining, brown; bar: 100 μm) and 
necrotic (HE; bar: 1 mm) compared to tumors growing in non-irradiated tissue (0 Gy). 
B, 4T1 tumors developing in pre-irradiated mammary tissue (20 Gy) were more 
invasive into fat (F) and muscle (M) tissues compared to control tumors (0 Gy) (bar: 
100 μm). C, 4T1 tumors developing in pre-irradiated mammary tissue (20 Gy) were 
more metastatic to ipsilateral lymph nodes compared to control tumors (0 Gy). A 
representative metastatic lymph node is shown in HE staining (bar: 50 μm). D, 4T1 
tumors growing in pre-irradiated mammary tissue (20 Gy) were highly metastatic to 
lungs compared to control tumors (0 Gy). Representative HE stained sections of 
lungs are shown (bar: 1 mm). Tumors were assessed at day 10 and metastases were 
at day 24 after tumor initiation. *p < 0.05 and **p < 0.01, n  5 mice per group. 
Results represent mean values ± SEM.  
 
Figure 2. Mobilized myeloid cells promote lung metastasis. A, 4T1 tumors 
growing in a pre-irradiated mammary tissue (20 Gy) were more densely infiltrated by 
CD11b+ cells compared to control tumors (0 Gy) and to tumor-free mammary fat 
pads. B, Myeloid cells (detected by F4/80 staining) accumulated preferentially at the 
periphery rather than in the center of tumors growing in pre-irradiated mammary 
tissue (20 Gy) compared to control tumors (0 Gy) (bars: 50 μm). Bottom graph shows 
data quantification (TC, tumor center; TP, tumor periphery). C, Clodrolip treatment 
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(15 days after tumor implantation) depleted CD11b+ cells from 4T1 tumors. D, 
Clodrolip treatment decreased lung metastasis of 4T1 tumors growing in a pre-
irradiated mammary tissue (20 Gy). Metastases were quantified 21 days after tumor 
initiation. Quantification of CD11b+ was done by flow cytometry, and F4/80+ by image 
analysis. *p < 0.05, **p < 0.01and ***p < 0.001. n  5 mice per group. Results 
represent mean values ± SEM.  
 
Figure 3. Hypoxia-induced KitL expression promotes metastasis. A, Hypoxia 
(0.1% O2, 24 hours) increased KitL protein release in 4T1 cell culture supernatant, 
which was inhibited by the HIF1-inhibitor NSC-134754 but not vehicle only (DMSO). 
B, 4T1 tumors growing in pre-irradiated mammary tissue (20 Gy) expressed higher 
KitL protein levels and treatment with NSC-134754 (NSC) prevented this increase. C, 
Elevated plasma KitL levels in mice bearing 4T1 tumors growing in pre-irradiated 
mammary tissue (20 Gy) relative to control mice (0 Gy). D, KitL-silencing (KitL-KD) 
suppressed lung metastasis of 4T1 tumors growing in pre-irradiated mammary tissue 
(20 Gy). Representative HE stained sections of corresponding lungs are shown (bar: 
1 mm). *p < 0.05, **p < 0.01 and ***p < 0.001. n  5 per group. Results represent 
mean values ± SEM.  
 
Figure 4. KitL mediates radiation-induced mobilization of c-Kit+ myeloid cells. 
A, c-Kit was expressed on a small fraction of bone marrow and blood-circulating cells 
of tumor-bearing mice but not on 4T1 cells in vitro or in vivo. Dotted line: staining by 
isotype control antibody. B, Myeloid c-Kit+ cells circulated at higher levels in the blood 
of mice bearing 4T1 tumor implanted in pre-irradiated mammary tissue (20 Gy) 
compared to non-irradiated mice (0 Gy). C, KitL silencing in 4T1 cells (KitL-KD) or 
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NSC-134754 (NSC) treatment decreased the number of circulating c-Kit+ cells in 
mice bearing 4T1 tumor implanted in a pre-irradiated mammary tissue (20 Gy). 
DMSO, vehicle control treatment.  
 
Figure 5. Mobilized CD11b+c-Kit+ cells home to tumors. A, CD11b+GFP+ isolated 
from 4T1 tumor-bearing, pre-irradiated, GFP+BALB/c mice were adoptively 
transferred to mice bearing 4T1 tumors implanted in pre-irradiated mammary tissues. 
Six hours after injection GFP+CD11b+ cells were detected in the blood and tumor. In 
the blood they partially retained (25%) c-Kit expression, while in the tumor they lost it. 
B, KitL silencing in 4T1 cells decreased CD11b+ cells in tumors growing in pre-
irradiated mammary tissue (20 Gy) compared to non-irradiated mice (0 Gy). C, 
CD11b+GFP+ cells isolated as in experiment of panel (A) were transferred into tumor-
bearing mice at a pre-metastatic stage. Six hours after injection, GFP+CD11b+ cells 
were detected in the lungs where they partially retained (25%) c-Kit expression. D, 
Increased frequency of GFP+CD11b+ was detected in pre-metastatic lungs of mice 
bearing tumors growing in pre-irradiated mammary tissue (20 Gy) compared to non-
irradiated mice (0 Gy). KitL silencing in 4T1 cells (KitL-KD) significantly decreased 
their level. NS, non-silencing control. Cell analysis was performed by flow cytometry. 
*p < 0.05, **p<0.01 and ***p < 0.001. n  5 mice per group. Results represent mean 
values ± SEM.  
 
Figure 6. C-Kit inhibition reduces CD11b+c-Kit+ cell mobilization and attenuates 
radiation-induced metastasis. A, Adoptive transfer of total mononuclear cells 
isolated from mice bearing 4T1 tumors growing in pre-irradiated mammary tissue into 
control mice implanted with 4T1 cells, increases lung metastasis. Depletion of c-Kit+ 
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cells in adoptively transferred PBMCs attenuated this effect by approximately 50%. B, 
Treatment of pre-irradiated, tumor-bearing mice with the anti-c-Kit mAb ACK2 
reduced the level of c-Kit+ cells in the blood (left panel) and of CD11b+ cells in the 
tumor (right panel). C, Treatment of pre-irradiated tumor-bearing mice with the anti-c-
Kit mAb ACK2 (upper panel) or with the tyrosine kinase inhibitor nilotinib (lower 
panel) significantly reduced lung metastasis. Control, vehicle only treatment. *p < 
0.05 and **p < 0.01. n  5 per group. Results represent mean values ± SEM. D, 
Working model of the identified mechanism promoting radiation-induced lung 
metastasis. Radiation-mediated inhibition of tumor angiogenesis causes tumor 
hypoxia, which induces KitL expression. Released KitL mobilizes CD11b+c-Kit+ cells 
that home to the tumor and lung to promote tumor metastasis.  
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